Scientific paper - Review paper
Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
Frontiers in Pharmacology, 12 (2021); 678546. https://doi.org/10.3389/fphar.2021.678546

Roguljic, Hrvoje; Nincevic, Vjera; Bojanic, Kristina; Kuna, Lucija; Smolic, Robert; Vcev, Aleksandar; Primorac, Dragan; Vceva, Andrijana; Wu, George Y.; Smolic, Martina

Cite this document

Roguljic, H., Nincevic, V., Bojanic, K., Kuna, L., Smolic, R., Vcev, A. ... Smolic, M. (2021). Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Frontiers in Pharmacology, 12.. doi: 10.3389/fphar.2021.678546

Roguljic, Hrvoje, et al. "Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update." Frontiers in Pharmacology, vol. 12, 2021. https://doi.org/10.3389/fphar.2021.678546

Roguljic, Hrvoje, Vjera Nincevic, Kristina Bojanic, Lucija Kuna, Robert Smolic, Aleksandar Vcev, Dragan Primorac, Andrijana Vceva, George Y. Wu and Martina Smolic. "Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update." Frontiers in Pharmacology 12 (2021). https://doi.org/10.3389/fphar.2021.678546

Roguljic, H., et al. (2021) 'Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update', Frontiers in Pharmacology, 12. doi: 10.3389/fphar.2021.678546

Roguljic H, Nincevic V, Bojanic K, Kuna L, Smolic R, Vcev A, and sur.. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Frontiers in Pharmacology [Internet]. 2021 [cited 2024 November 26];12. doi: 10.3389/fphar.2021.678546

H. Roguljic, et al., "Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update", Frontiers in Pharmacology, vol. 12, 2021. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:396498. [Accessed: 26 November 2024]